These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8683698)

  • 21. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Stanislaus P; Seitz M
    Eur Urol; 2009 Apr; 55(4):909-10. PubMed ID: 18485577
    [No Abstract]   [Full Text] [Related]  

  • 22. Management of rising prostate-specific antigen following a negative biopsy.
    Jones JS
    Curr Opin Urol; 2010 May; 20(3):198-203. PubMed ID: 20583345
    [No Abstract]   [Full Text] [Related]  

  • 23. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
    Hambrock T; Somford DM; Hoeks C; Bouwense SA; Huisman H; Yakar D; van Oort IM; Witjes JA; Fütterer JJ; Barentsz JO
    J Urol; 2010 Feb; 183(2):520-7. PubMed ID: 20006859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
    BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
    Djavan B; Fong YK; Ravery V; Remzi M; Horninger W; Susani M; Kreuzer S; Boccon-Gibod L; Bartsch G; Marberger M
    Eur Urol; 2005 Jan; 47(1):38-44; discussion 44. PubMed ID: 15582247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial comment.
    Schilling D; Stenzl A
    J Urol; 2010 Feb; 183(2):527-8; discussion 528. PubMed ID: 20006885
    [No Abstract]   [Full Text] [Related]  

  • 27. [New urinary markers in patients with prostatic cancer: analysis of the screening problem].
    Jiménez-Pacheco A; Peinado-Herreros JM; López-Luque A; Iríbar Ibabe MC
    Rev Med Chil; 2012 May; 140(5):686-7. PubMed ID: 23096680
    [No Abstract]   [Full Text] [Related]  

  • 28. Could prostate biopsies be avoided in men older than 75 years with raised PSA?
    Nomikos M; Mariappan P; Zachou A; McNeill A; Bollina PR
    Urol Int; 2010; 85(4):410-4. PubMed ID: 20962505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editorial: Lessons learned from prostate biopsies.
    McCullough DL
    J Urol; 2002 Nov; 168(5):2000. PubMed ID: 12394694
    [No Abstract]   [Full Text] [Related]  

  • 30. Transrectal prostate biopsy.
    Ismail MT; Gomella LG
    Urol Clin North Am; 2013 Nov; 40(4):457-72. PubMed ID: 24182969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies.
    Gilbert SM; Cavallo CB; Kahane H; Lowe FC
    Urology; 2005 Mar; 65(3):549-53. PubMed ID: 15780374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of transition zone prostate biopsies in patients with gray-zone PSA levels undergoing the ultrasound-guided systematic ten-biopsy regimen for the first time.
    Ishizuka O; Mimura Y; Oguchi T; Kawakami M; Nishizawa O
    Urol Int; 2005; 74(1):23-6. PubMed ID: 15711104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy.
    Ohigashi T; Kanao K; Kikuchi E; Nakagawa K; Nakashima J; Marumo K; Murai M
    J Urol; 2005 May; 173(5):1541-5. PubMed ID: 15821482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The interplay between obesity and the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer.
    Granieri MA; Freedland SJ
    BJU Int; 2013 Aug; 112(4):E272. PubMed ID: 23879911
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy.
    Fujita K; Hosomi M; Tanigawa G; Okumi M; Fushimi H; Yamaguchi S
    J Urol; 2011 May; 185(5):1722-7. PubMed ID: 21420119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prostatic punch biopsy].
    Braun M; Engelmann U
    Aktuelle Urol; 2006 Jul; 37(4):291-302. PubMed ID: 16897646
    [No Abstract]   [Full Text] [Related]  

  • 37. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
    Stephan C; Lein M; Schnorr D; Loening SA; Jung K
    BJU Int; 2004 Jun; 93(9):1360-1. PubMed ID: 15180645
    [No Abstract]   [Full Text] [Related]  

  • 38. [Prostate biopsy: assessment of current indications and techniques].
    Introini C; Puppo P
    Arch Ital Urol Androl; 2000 Dec; 72(4):150-60. PubMed ID: 11221028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number.
    Ploussard G; Azancot V; Nicolaiew N; Xylinas E; Salomon L; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    BJU Int; 2010 Nov; 106(9):1293-7. PubMed ID: 20456338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.